Getting Medicare to pay for your medical test is the healthcare equivalent of getting your product onto Costco shelves. It's a big deal, and Personalis Inc. (PSNL) just cleared that hurdle. The company announced Medicare coverage for its NeXT Personal molecular residual disease test for lung cancer surveillance, sending shares up 14.90% to $8.99 in premarket trading Tuesday.
The broader market was already in a decent mood, with the Nasdaq up 0.33% and the S&P 500 up 0.22% on the previous trading day, but this news gave Personalis its own reason to celebrate.
What's Actually Happening Here
Personalis announced that Medicare will now cover its NeXT Personal test for patients with Stage I to III non-small cell lung cancer. This isn't just some routine lab work. The test uses advanced genomic sequencing to track up to 1,800 mutations, giving doctors a powerful tool to monitor whether cancer is coming back or if residual disease is lurking after treatment.
The clinical proof backing this up comes from the TRACERx collaboration, which validated the test's accuracy in identifying residual disease. CEO Chris Hall made it clear this isn't just about helping patients (though that's obviously important). It's also a growth catalyst for the company as it pushes deeper into the oncology market. And considering lung cancer remains one of the leading causes of cancer death in the United States, with tens of thousands of new cases diagnosed every year, the addressable market is substantial.
The Technical Picture
Despite Tuesday's premarket surge, the stock has been dealing with some technical headwinds. It's trading 16.6% below its 20-day simple moving average and 13.7% below its 50-day SMA, which points to recent short-term weakness. But zoom out a bit and the picture improves: the stock is trading 4.3% above its 100-day SMA and 21.1% above its 200-day SMA, suggesting a stronger long-term trend. Over the past year, shares have climbed 56.29% and are sitting closer to their 52-week highs than their lows.
The RSI currently sits at 39.64, which is neutral territory, while the MACD is below its signal line, indicating some bearish pressure. It's a mixed bag in terms of momentum, so traders should keep an eye out for potential shifts in either direction.
Key resistance is sitting at $10.00, while support is around $7.50. The Medicare coverage news could be the catalyst that pushes the stock through that resistance level if momentum builds.
What Analysts Are Saying
Wall Street seems to like what it sees. The stock carries a Buy rating with an average price target of $11.78, which would represent solid upside from current levels. Recent analyst activity includes Guggenheim raising its target to $13.00 on January 26, BTIG maintaining a Buy rating with a $12.00 target on January 9, and Morgan Stanley assigning an Equal-Weight rating with an $11.00 target back on December 2, 2025.
Investors have the next earnings report circled on their calendars for February 26, 2026. The consensus estimates call for a loss of 29 cents per share, which is actually wider than the 23-cent loss from the same period last year. But revenue is expected to grow to $17.55 million, up from $16.80 million year-over-year. It's the classic biotech story: spending money now to build something bigger later.
Momentum Scorecard
According to market data, Personalis scores a 92.11 on momentum metrics, which is considered bullish. The stock is outperforming the broader market, and that strong momentum signal, combined with the Medicare coverage announcement, positions the company favorably heading into the next phase of growth.
ETF Exposure Worth Watching
If you're tracking Personalis, you should also be watching the ARK Genomic Revolution ETF (ARKG), where the stock carries a 6.35% weight. That's significant because any major inflows or outflows into the ETF will likely force automatic buying or selling of PSNL shares, which can amplify price movements in either direction.
The Medicare decision marks a significant milestone for Personalis, potentially opening the floodgates for broader adoption of its genomic solutions. Now the company needs to execute on converting that access into actual revenue growth. The market seems optimistic, but as always with biotech, the proof will be in the numbers when earnings season arrives.
